Brexit: RPs for Import from the EU

Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
The scenario of a so called "Hard Brexit" (the United Kingdom - UK - to leave the EU with no deal) is still a possibility. All parties involved started plans for such eventuality, including governments and authorities.
The UK Government has been preparing legislation to allow the continued sale of and access to medicines manufactured in the remaining EU. An updated guidance document further clarifies the possibility to distribute products certified by a EU Qualified Person (QP): "If there is a no-deal Brexit, a wholesale dealer may import EU-QP certified medicines form the European Economic Area (EEA*) if certain checks are made by the 'Responsible Person (import) (RPi)'."
This RP is required to implement a system for confirming EU QP certification has taken place when importing products into the UK from EEA.
MHRA points out that an RPi plays "an important role in ensuring the safe control of medicines" and lays down in detail how to become an RPi and how to apply.
* The EEA compromises the remaining EU Member States and three European Free Trade Association (EFTA) states Iceland, Liechtenstein, and Norway into one internal market area governed by the same basic rules.
Related GMP News
10.06.2025Stimuli Article Proposes Revision of USP Definition of Controlled Room Temperature (CRT)
10.06.2025New MHRA Blog Post: Supplying Medicines to Ships, Aircraft and Oil Platforms
10.06.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 3
10.06.2025Meet the GDPA Board Members at the GDP Forum in Barcelona
10.06.2025Swissmedic Technical Interpretation: What Counts as a Major Change in GDP?
10.06.2025MHRA informes about Validity Date of UK issued GDP Certificates